BIOTIN ( DrugBank: Biotin )


5 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2
8Huntington disease2
10Charcot-Marie-Tooth disease1
13Multiple sclerosis/Neuromyelitis optica12
20Adrenoleukodystrophy1

2. Amyotrophic lateral sclerosis


Clinical trials : 645Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

8. Huntington disease


Clinical trials : 242Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

10. Charcot-Marie-Tooth disease


Clinical trials : 41Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 61Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries